Skip to main content
S&P 5007,623.68-0.52%DOW52,215.16-1.23%NASDAQ25,955.34-0.21%BTC$80,645.00-0.98%ETH$2,373.55-0.82%GOLD$4,010.00-1.24%OIL$103.44+3.99%
Smart Investors Daily
SID Premium
MR

NASDAQ · MRVI

Maravai LifeSciences Holdings, Inc.

Healthcare · Biotechnology

$7.32

Up+$0.25 (+3.54%)

Updated Oct 24, 2026, 11:56 PM

SID Score

5.8/10

Composite research score

Smart Money

—

Institutional and insider signal

Market cap
1.03B
P/E ratio
-4.43
Dividend yield
0.00%
52-week range
$2.55 – $9.42
Volume
1.45M
Avg. volume
1.5M

Price performance · MRVI

MRVI price history

1M range · 21 trading sessions · Daily adjusted prices

Prices through Oct 23, 2026

MRVI closed at $7.32 after 21 trading sessions, down 3.68% for the selected period.

Last close
$7.32
Period change
-3.68%
Period low
$6.53
Period high
$8.52
Daily close
View OHLC price history
MRVI OHLC price history, latest 40 sessions
DateOpenHighLowCloseVolume
Oct 23, 2026$7.03$7.33$6.98$7.321.45M
Oct 22, 2026$7.44$7.61$6.73$7.073.92M
Oct 21, 2026$7.18$7.615$7.18$7.571.7M
Oct 20, 2026$6.99$7.595$6.985$7.202.02M
Oct 19, 2026$6.79$7.02$6.69$6.991.35M
Oct 16, 2026$7.05$7.08$6.735$6.792.24M
Oct 15, 2026$6.70$7.15$6.51$7.072.37M
Oct 14, 2026$6.41$6.67$6.334$6.552.74M
Oct 13, 2026$6.95$7.06$6.52$6.534.33M
Oct 12, 2026$7.38$7.381$6.95$7.061.25M
Oct 9, 2026$7.25$7.52$7.17$7.442.31M
Oct 8, 2026$7.31$7.37$7.01$7.213.59M
Oct 7, 2026$7.65$7.73$7.22$7.434.27M
Oct 6, 2026$8.54$8.74$7.765$7.853.61M
Oct 5, 2026$8.015$8.575$7.80$8.522.63M
Oct 2, 2026$7.62$7.92$7.50$7.901.91M
Oct 1, 2026$7.67$7.73$7.325$7.504.34M
Sep 30, 2026$7.65$7.75$7.53$7.663.61M
Sep 29, 2026$7.52$7.70$7.435$7.651.76M
Sep 28, 2026$7.49$7.68$7.40$7.631.94M
Sep 25, 2026$7.61$7.65$7.245$7.601.93M

Latest MRVI news

The latest Smart Investors Daily articles mentioning MRVI.

Stock researchCompany · Overview

MRVI research

Overview

Company profile and research snapshot.

Company profile

Maravai LifeSciences Holdings Inc is a life sciences company that provides critical products that drive the development of groundbreaking vaccines, drug therapies, cell and gene therapies, and diagnostics. The group's solutions empower research into human diseases and support the entire biopharmaceutical development process from early discovery to commercialization. Its reportable segments are Nucleic acid production and biologics safety testing. It generates a majority of its revenue from Nucleic Acid Production and focuses on the manufacturing and sale of nucleic acid products to support the needs of customers' research, and therapeutic and vaccine programs. In addition, the segment also provides research products for labeling and detecting proteins in cells and tissue samples.

Visit company website

Analyst outlook

Consensus and target data currently published for this company.

Consensus
—
Average target
$15.50
Implied upside
—
Analysts
—
MRVI recent ratings
DateFirmRatingTarget
Sep 9, 2026UBSNeutral—
Aug 7, 2026Wells FargoOverweight—
May 8, 2026Wells FargoOverweight—
Dec 15, 2025Wells FargoOverweight—
Aug 12, 2025RBC CapitalOutperform—
Open full forecast

News briefing

No generated briefing is available yet.

Yahoo · Oct 17, 2026

Maravai LifeSciences (MRVI) Stock Gets Fair Value Boost On mRNA And CleanCap Optimism

The fair value estimate for Maravai LifeSciences Holdings has shifted from US$7.60 to US$8.50, giving investors a refreshed anchor for where some analysts currently see the stock’s worth. This move lines up with recent research that highlights upside potential tied to mRNA exposure and CleanCap revenue momentum, while still flagging execution risk and a more measured view on broader life science tools demand. As you read on, you will see how this updated valuation fits into the evolving...

Yahoo · Oct 14, 2026

Maravai LifeSciences To Host Earnings Conference Call on Wednesday, November 4, 2026

SAN DIEGO, October 14, 2026--Maravai LifeSciences, Inc. (Maravai) (NASDAQ: MRVI), a global provider of life science reagents and services to researchers and biotech innovators, plans to announce its third quarter financial and operating results after the market close on Wednesday, November 4, 2026, and will host a conference call and webcast on the same day at 2:00 p.m. PT/ 5:00 p.m. ET.

Benzinga · Oct 13, 2026

Full Transcript: Maravai LifeSciences Q2 2026 Earnings Call

Maravai LifeSciences (NASDAQ:MRVI) reported second-quarter financial results on Thursday. The transcript from the company's second-quarter earnings call has been provided below. This transcript is brought to you by

Yahoo · Oct 4, 2026

What Is Maravai’s (MRVI) Comeback Really Worth to Investors?

Maravai LifeSciences (NASDAQ:MRVI) enters 2026 at a strategic inflection point, balancing its post-pandemic operational transition against a core business model rooted in high-margin nucleic acid production and bioprocess impurity testing. With a market capitalization hovering near $2 billion against full-year revenue guidance of $205 million to $215 million, the company carries a structured balance sheet […]

AI research layers

Interpretive context generated from the platform’s current data sources.

No results

AI research layers have not been published yet.

Featured By